Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections - Full Text View

Purpose

The purpose of this study is to evaluate the effects of Delafloxacin versus Vancomycin plus Aztreonam in the treatment of patients with complicated bacterial and soft tissue infections.

Condition	Intervention	Phase
Acute Bacterial Skin Infection Skin Structure Infection	Drug: delafloxacin Drug: vancomycin	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A Phase 3, Multicenter, Randomized, Double-blind, Active Controlled Study to Evaluate the Efficacy + Safety of IV + Oral Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections

Resource links provided by NLM:

MedlinePlus related topics: Skin Infections

Drug Information available for: Vancomycin Vancomycin hydrochloride Aztreonam

U.S. FDA Resources

Further study details as provided by Melinta Therapeutics, Inc.:

Primary Outcome Measures:

Objective response of ≥20% reduction in lesion erythema area compared to baseline at 48 to 72 hours after initiation of treatment as determined by digital measurements of the leading edge. [ Time Frame: Baseline and at 48 to 72 hrs ] [ Designated as safety issue: No ]
Digital photography of the infection area will be obtained at Screening, Day 1, Day 2, twice on Day 3 (12 hours apart), Day 4, Day 5, End of Treatment, Follow up, and Late Follow up using the equipment provided. The photography will be analyzed for planimetry measurements and used in the objective response assessments.

Secondary Outcome Measures:

Investigator-assessed response of signs and symptoms of infection at the Follow up Visit (EMA primary endpoint) [ Time Frame: Up to Day 14±1 ] [ Designated as safety issue: No ]
Investigator-assessed response of signs and symptoms of infection in patients with a baseline BMI ≥30 at the Follow up Visit [ Time Frame: Up to14 ± 1 days after initiation of treatment ] [ Designated as safety issue: No ]
Investigator-assessed response of signs and symptoms of infection at the Late Follow-up Visit [ Time Frame: Up to Day 28 ] [ Designated as safety issue: No ]
Reduction of erythema of ≥30% at 48 to 72 hours when digital measurements are used [ Time Frame: at 48 and 72 hrs ] [ Designated as safety issue: No ]
Reduction in pain at End of Treatment as measured by ePRO system [ Time Frame: Up to Day 14 ] [ Designated as safety issue: No ]
Microbiological response of eradicated (documented or presumed) at the Follow-up Visit in all patients [ Time Frame: Up to Day 14 ] [ Designated as safety issue: No ]


Estimated Enrollment:	660
Study Start Date:	May 2014
Estimated Study Completion Date:	July 2015
Estimated Primary Completion Date:	May 2015 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Delafloxacin 300mg iv Q12H for 6 doses, 450mg oral tablet Q12H for up to 10 - 28 doses total	Drug: delafloxacin 1
Active Comparator: Vancomycin plus Aztreonam Vancomycin 15mg/kg iv plus two grams Aztreonam every 12 hours for up to 10 to 28 doses	Drug: vancomycin 2

Detailed Description:

The purpose of this study is to evaluate the effects of Delafloxacin versus Vancomycin plus Aztreonam in the treatment of patients with complicated bacterial and soft tissue infections.

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Adult (≥ 18 years of age) men or women with a diagnosis of ABSSSI (cellulitis/erysipelas, wound infection, major cutaneous abscess, or burn infection) with at least two signs of systemic infection
In the opinion of the investigator, the subject must require and be a suitable candidate for IV antibiotic therapy, and the subject must be able and willing to comply with protocol requirements

Exclusion Criteria:

A medical history of significant hypersensitivity or allergic reaction to quinolones, beta-lactams, vancomycin, or vancomycin derivatives according to the judgment of the investigator.
Women who are pregnant or lactating.
Any chronic or underlying skin condition at the site of infection that may complicate the assessment of response, including infection involving a prosthetic joint, human or animal bite, osteomyelitis, decubitus ulcer, diabetic foot ulcer, septic arthritis, mediastinitis, necrotizing fasciitis, anaerobic cellulitis, or synergistic necrotizing cellulitis, myositis, tendinitis, endocarditis, sustained shock, gangrene or gas gangrene; burns covering ≥10% of body surface area; severely compromised immune system, severely impaired arterial blood supply to an extremity with an ABSSSI, deep vein thrombosis or superficial thrombophlebitis, and requiring either an amputation or multiple debridement procedures.
Any underlying disease that, in the opinion of the investigator, could interfere with the subject's ability to participate in the study including severe cardiac disease, known history of liver disease, end-stage renal disease, malignancy, psychiatric disorder, ongoing treatment for seizures or untreated history of seizures, or life expectancy of < 3 months.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01984684

Contacts


Contact: Sue K Cammarata, MD	203-848-3342	clinicaltrials@melinta.com

Locations


United States, Alabama
Melinta 303 Study Site	Recruiting
Mobile, Alabama, United States, 36607
United States, California
Melinta 303 Study Site	Recruiting
Chula Vista, California, United States, 91911
Melinta 303 Study Site	Recruiting
La Mesa, California, United States, 91942
Melinta 303 Study Site	Recruiting
Oceanside, California, United States, 92056
Melinta 303 Study Site	Recruiting
San Diego, California, United States, 92114
Melinta 303 Study Site	Recruiting
Torrance, California, United States, 90509
United States, Georgia
Melinta 303 Study Site	Recruiting
Columbus, Georgia, United States, 31904
Melinta 303 Study Site	Recruiting
Savannah, Georgia, United States, 31405
United States, Louisiana
Melinta 303 Study Site	Not yet recruiting
Eunice, Louisiana, United States, 70535
United States, Minnesota
Melinta 303 Study Site	Recruiting
Minneapolis, Minnesota, United States, 55422
United States, Nevada
Melinta 303 Study Site	Recruiting
Las Vegas, Nevada, United States, 89109
United States, New Jersey
Melinta 303 Study Site	Recruiting
Somers Point, New Jersey, United States, 08244
United States, Texas
Melinta 303 Study Site	Recruiting
Channelview, Texas, United States, 77530
Melinta 303 Study Site	Recruiting
Houston, Texas, United States, 77024

Sponsors and Collaborators

Melinta Therapeutics, Inc.

Investigators


Study Director:	Sue K Cammarata, MD	Melinta Therapeutics, Inc.

More Information

No publications provided


Responsible Party:	Melinta Therapeutics, Inc.
ClinicalTrials.gov Identifier:	NCT01984684 History of Changes
Other Study ID Numbers:	RX-3341-303
Study First Received:	November 8, 2013
Last Updated:	January 27, 2015
Health Authority:	United States: Food and Drug Administration

Keywords provided by Melinta Therapeutics, Inc.:


Bacterial skin infection infection skin delafloxacin vancomycin	aztreonam MRSA bacteria bacterial infection Anti-Infective Agents

Additional relevant MeSH terms:


Communicable Diseases Infection Bacterial Infections Skin Diseases, Infectious Skin Diseases, Bacterial Skin Diseases	Aztreonam Vancomycin Anti-Bacterial Agents Anti-Infective Agents Pharmacologic Actions Therapeutic Uses

ClinicalTrials.gov processed this record on March 03, 2015